Decibel Therapeutics Added to Russell 2000 Index
22 mars 2021 08h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, March 22, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX) (“Decibel”), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments...
Decibel Therapeutics to Present at the Barclays Global Healthcare Conference
04 mars 2021 08h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations
24 févr. 2021 07h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage company developing treatments to restore and improve hearing and balance, presented preclinical data...
Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference
19 févr. 2021 07h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Announces Pricing of Initial Public Offering
11 févr. 2021 21h51 HE
|
Decibel Therapeutics, Inc.
BOSTON, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...